Could a stem cell drug tame rare immune disease?
NCT ID NCT00967785
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 7 times
Summary
This early-phase study tests whether Mozobil, a drug already used to boost stem cells for transplants, can safely raise white blood cell counts in people with WHIMS. WHIMS is a rare genetic condition that traps infection-fighting cells in the bone marrow, leading to frequent infections. Up to 20 adults aged 18-75 will receive Mozobil injections, with some continuing treatment for up to 5 years, to see if it reduces infections and warts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a simple shot under the skin replace an IV for a key antibiotic in the elderly?
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Experimental malaria vaccine aims to block parasite growth
- Can a blister beetle extract banish common warts? phase 3 trial investigates